

William B Isaacs

List of Publications by Year in Descending Order

Source: <https://exaly.com/author-pdf/765528/william-b-isaacs-publications-by-year.pdf>

Version: 2024-04-28

This document has been generated based on the publications and citations recorded by exaly.com. For the latest version of this publication list, visit the link given above.

The third column is the impact factor (IF) of the journal, and the fourth column is the number of citations of the article.

340
papers

31,364
citations

89
h-index

168
g-index

359
ext. papers

35,490
ext. citations

8.6
avg, IF

6.43
L-index

#	Paper	IF	Citations
340	Association of germline rare pathogenic mutations in guideline-recommended genes with prostate cancer progression: A meta-analysis. <i>Prostate</i> , 2022 , 82, 107-119	4.2	2
339	Germline BRCA2, ATM and CHEK2 alterations shape somatic mutation landscapes in prostate cancer.. <i>Journal of Clinical Oncology</i> , 2022 , 40, 148-148	2.2	
338	Resistance to androgen receptor signaling inhibition does not necessitate development of neuroendocrine prostate cancer. <i>JCI Insight</i> , 2021 , 6,	9.9	5
337	Association of prostate cancer polygenic risk score with number and laterality of tumor cores in active surveillance patients. <i>Prostate</i> , 2021 , 81, 703-709	4.2	2
336	The somatic mutation landscape of germline CHEK2-altered prostate cancer.. <i>Journal of Clinical Oncology</i> , 2021 , 39, 5084-5084	2.2	0
335	Specific Detection of Prostate Cancer Cells in Urine by RNA In Situ Hybridization. <i>Journal of Urology</i> , 2021 , 206, 37-43	2.5	1
334	Two-stage Study of Familial Prostate Cancer by Whole-exome Sequencing and Custom Capture Identifies 10 Novel Genes Associated with the Risk of Prostate Cancer. <i>European Urology</i> , 2021 , 79, 353-361	10.2	9
333	Performance of Three Inherited Risk Measures for Predicting Prostate Cancer Incidence and Mortality: A Population-based Prospective Analysis. <i>European Urology</i> , 2021 , 79, 419-426	10.2	8
332	A novel method for detection of exfoliated prostate cancer cells in urine by RNA in situ hybridization. <i>Prostate Cancer and Prostatic Diseases</i> , 2021 , 24, 220-232	6.2	
331	Trans-ancestry genome-wide association meta-analysis of prostate cancer identifies new susceptibility loci and informs genetic risk prediction. <i>Nature Genetics</i> , 2021 , 53, 65-75	36.3	62
330	Homologous recombination deficiency (HRD) score in germline BRCA2- versus ATM-altered prostate cancer. <i>Modern Pathology</i> , 2021 , 34, 1185-1193	9.8	15
329	Observed evidence for guideline-recommended genes in predicting prostate cancer risk from a large population-based cohort. <i>Prostate</i> , 2021 , 81, 1002-1008	4.2	2
328	Genetic Susceptibility for Low Testosterone in Men and Its Implications in Biology and Screening: Data from the UK Biobank. <i>European Urology Open Science</i> , 2021 , 29, 36-46	0.9	0
327	Prostate Cancer Predisposition. <i>Urologic Clinics of North America</i> , 2021 , 48, 283-296	2.9	6
326	Rare Germline Variants in ATM Predispose to Prostate Cancer: A PRACTICAL Consortium Study. <i>European Urology Oncology</i> , 2021 , 4, 570-579	6.7	12
325	Combined Longitudinal Clinical and Autopsy Phenomic Assessment in Lethal Metastatic Prostate Cancer: Recommendations for Advancing Precision Medicine. <i>European Urology Open Science</i> , 2021 , 30, 47-62	0.9	2
324	Association between pathogenic germline mutations in BRCA2 and ATM and tumor-infiltrating lymphocytes in primary prostate cancer. <i>Cancer Immunology, Immunotherapy</i> , 2021 , 1	7.4	0

323	A Germline Variant at 8q24 Contributes to Familial Clustering of Prostate Cancer in Men of African Ancestry. <i>European Urology</i> , 2020 , 78, 316-320	10.2	13
322	Implementation of Germline Testing for Prostate Cancer: Philadelphia Prostate Cancer Consensus Conference 2019. <i>Journal of Clinical Oncology</i> , 2020 , 38, 2798-2811	2.2	80
321	Use of Aspirin and Statins in Relation to Inflammation in Benign Prostate Tissue in the Placebo Arm of the Prostate Cancer Prevention Trial. <i>Cancer Prevention Research</i> , 2020 , 13, 853-862	3.2	0
320	Rare Germline Pathogenic Mutations of DNA Repair Genes Are Most Strongly Associated with Grade Group 5 Prostate Cancer. <i>European Urology Oncology</i> , 2020 , 3, 224-230	6.7	17
319	Distinct Genomic Alterations in Prostate Tumors Derived from African American Men. <i>Molecular Cancer Research</i> , 2020 , 18, 1815-1824	6.6	3
318	Germline BLM mutations and metastatic prostate cancer. <i>Prostate</i> , 2020 , 80, 235-237	4.2	8
317	Role of androgen receptor splice variant-7 (AR-V7) in prostate cancer resistance to 2nd-generation androgen receptor signaling inhibitors. <i>Oncogene</i> , 2020 , 39, 6935-6949	9.2	19
316	Genomic and Clinicopathologic Characterization of -deficient Prostate Cancer. <i>Clinical Cancer Research</i> , 2020 , 26, 4869-4881	12.9	6
315	Validation of a prostate cancer polygenic risk score. <i>Prostate</i> , 2020 , 80, 1314-1321	4.2	6
314	Feasibility and performance of a novel probe panel to detect somatic DNA copy number alterations in clinical specimens for predicting prostate cancer progression. <i>Prostate</i> , 2020 , 80, 1253-1262	4.2	1
313	Germline HOXB13 G84E mutation carriers and risk to twenty common types of cancer: results from the UK Biobank. <i>British Journal of Cancer</i> , 2020 , 123, 1356-1359	8.7	8
312	Inherited risk assessment of prostate cancer: it takes three to do it right. <i>Prostate Cancer and Prostatic Diseases</i> , 2020 , 23, 59-61	6.2	5
311	Lactoferrin CpG Island Hypermethylation and Decoupling of mRNA and Protein Expression in the Early Stages of Prostate Carcinogenesis. <i>American Journal of Pathology</i> , 2019 , 189, 2311-2322	5.8	4
310	Concept and benchmarks for assessing narrow-sense validity of genetic risk score values. <i>Prostate</i> , 2019 , 79, 1099-1105	4.2	7
309	Trichomonas vaginalis infection and prostate-specific antigen concentration: Insights into prostate involvement and prostate disease risk. <i>Prostate</i> , 2019 , 79, 1622-1628	4.2	8
308	ATM loss in primary prostate cancer: Analysis of >1000 cases using a validated clinical-grade immunohistochemistry (IHC) assay.. <i>Journal of Clinical Oncology</i> , 2019 , 37, 5069-5069	2.2	2
307	Current progress and questions in germline genetics of prostate cancer. <i>Asian Journal of Urology</i> , 2019 , 6, 3-9	2.7	7
306	Molecular Characterization and Clinical Outcomes of Primary Gleason Pattern 5 Prostate Cancer After Radical Prostatectomy. <i>JCO Precision Oncology</i> , 2019 , 3,	3.6	7

305	Single-Nucleotide Polymorphism-Based Genetic Risk Score and Patient Age at Prostate Cancer Diagnosis. <i>JAMA Network Open</i> , 2019 , 2, e1918145	10.4	10
304	Mannose Receptor-positive Macrophage Infiltration Correlates with Prostate Cancer Onset and Metastatic Castration-resistant Disease. <i>European Urology Oncology</i> , 2019 , 2, 429-436	6.7	23
303	HOXB13 interaction with MEIS1 modifies proliferation and gene expression in prostate cancer. <i>Prostate</i> , 2019 , 79, 414-424	4.2	24
302	Germline Mutations in ATM and BRCA1/2 Are Associated with Grade Reclassification in Men on Active Surveillance for Prostate Cancer. <i>European Urology</i> , 2019 , 75, 743-749	10.2	71
301	A systematic comparison of exercise training protocols on animal models of cardiovascular capacity. <i>Life Sciences</i> , 2019 , 217, 128-140	6.8	20
300	Updated insights into genetic contribution to prostate cancer predisposition: focus on HOXB13. <i>Canadian Journal of Urology</i> , 2019 , 26, 12-13	0.8	4
299	A comprehensive evaluation of CHEK2 germline mutations in men with prostate cancer. <i>Prostate</i> , 2018 , 78, 607-615	4.2	33
298	Sequencing of prostate cancers identifies new cancer genes, routes of progression and drug targets. <i>Nature Genetics</i> , 2018 , 50, 682-692	36.3	112
297	Germline DNA-repair Gene Mutations and Outcomes in Men with Metastatic Castration-resistant Prostate Cancer Receiving First-line Abiraterone and Enzalutamide. <i>European Urology</i> , 2018 , 74, 218-225	10.2	107
296	Intraductal/ductal histology and lymphovascular invasion are associated with germline DNA-repair gene mutations in prostate cancer. <i>Prostate</i> , 2018 , 78, 401-407	4.2	68
295	Differences in inherited risk among relatives of hereditary prostate cancer patients using genetic risk score. <i>Prostate</i> , 2018 , 78, 1063	4.2	1
294	Germline mutations in PPFIBP2 are associated with lethal prostate cancer. <i>Prostate</i> , 2018 , 78, 1222-1228	4.2	5
293	Constitutively active androgen receptor splice variants AR-V3, AR-V7 and AR-V9 are co-expressed in castration-resistant prostate cancer metastases. <i>British Journal of Cancer</i> , 2018 , 119, 347-356	8.7	38
292	Germline mutations in DNA repair genes are associated with bladder cancer risk and unfavourable prognosis. <i>BJU International</i> , 2018 , 122, 808-813	5.6	12
291	Sustained influence of infections on prostate-specific antigen concentration: An analysis of changes over 10 years of follow-up. <i>Prostate</i> , 2018 , 78, 1024-1034	4.2	3
290	Effect of germline DNA repair gene mutations on outcomes in men with metastatic castration-resistant prostate cancer receiving first-line abiraterone and enzalutamide.. <i>Journal of Clinical Oncology</i> , 2018 , 36, 221-221	2.2	
289	Genetic factors influencing prostate cancer risk in Norwegian men. <i>Prostate</i> , 2018 , 78, 186-192	4.2	9
288	Role of Genetic Testing for Inherited Prostate Cancer Risk: Philadelphia Prostate Cancer Consensus Conference 2017. <i>Journal of Clinical Oncology</i> , 2018 , 36, 414-424	2.2	107

287	gsSKAT: Rapid gene set analysis and multiple testing correction for rare-variant association studies using weighted linear kernels. <i>Genetic Epidemiology</i> , 2017 , 41, 297-308	2.6	5
286	Analytic, Preanalytic, and Clinical Validation of p53 IHC for Detection of Missense Mutation in Prostate Cancer. <i>Clinical Cancer Research</i> , 2017 , 23, 4693-4703	12.9	39
285	Association between variants in genes involved in the immune response and prostate cancer risk in men randomized to the finasteride arm in the Prostate Cancer Prevention Trial. <i>Prostate</i> , 2017 , 77, 908-919	4.3	16
284	Germline Mutations in ATM and BRCA1/2 Distinguish Risk for Lethal and Indolent Prostate Cancer and are Associated with Early Age at Death. <i>European Urology</i> , 2017 , 71, 740-747	10.2	171
283	Appraising the relevance of DNA copy number loss and gain in prostate cancer using whole genome DNA sequence data. <i>PLoS Genetics</i> , 2017 , 13, e1007001	6	20
282	Insight into infection-mediated prostate damage: Contrasting patterns of C-reactive protein and prostate-specific antigen levels during infection. <i>Prostate</i> , 2017 , 77, 1325-1334	4.2	8
281	MSH2 Loss in Primary Prostate Cancer. <i>Clinical Cancer Research</i> , 2017 , 23, 6863-6874	12.9	78
280	A genetic variant near GATA3 implicated in inherited susceptibility and etiology of benign prostatic hyperplasia (BPH) and lower urinary tract symptoms (LUTS). <i>Prostate</i> , 2017 , 77, 1213-1220	4.2	15
279	The expression of AURKA is androgen regulated in castration-resistant prostate cancer. <i>Scientific Reports</i> , 2017 , 7, 17978	4.9	23
278	Somatic molecular subtyping of prostate tumors from HOXB13 G84E carriers. <i>Oncotarget</i> , 2017 , 8, 22772-22788	3.3	33
277	Germline Variants in Asporin Vary by Race, Modulate the Tumor Microenvironment, and Are Differentially Associated with Metastatic Prostate Cancer. <i>Clinical Cancer Research</i> , 2016 , 22, 448-58	12.9	19
276	Rare Variation in TET2 Is Associated with Clinically Relevant Prostate Carcinoma in African Americans. <i>Cancer Epidemiology Biomarkers and Prevention</i> , 2016 , 25, 1456-1463	4	14
275	DNA-Repair Gene Mutations in Metastatic Prostate Cancer. <i>New England Journal of Medicine</i> , 2016 , 375, 1802-1803	59.2	7
274	Screening for familial and hereditary prostate cancer. <i>International Journal of Cancer</i> , 2016 , 138, 2579-917.5	17.5	33
273	Genome-wide association of familial prostate cancer cases identifies evidence for a rare segregating haplotype at 8q24.21. <i>Human Genetics</i> , 2016 , 135, 923-38	6.3	27
272	Identification of miR-30b-3p and miR-30d-5p as direct regulators of androgen receptor signaling in prostate cancer by complementary functional microRNA library screening. <i>Oncotarget</i> , 2016 , 7, 72593-72607	3.3	51
271	Post hoc Analysis for Detecting Individual Rare Variant Risk Associations Using Probit Regression Bayesian Variable Selection Methods in Case-Control Sequencing Studies. <i>Genetic Epidemiology</i> , 2016 , 40, 461-9	2.6	3
270	Adding genetic risk score to family history identifies twice as many high-risk men for prostate cancer: Results from the prostate cancer prevention trial. <i>Prostate</i> , 2016 , 76, 1120-9	4.2	42

269	Genetic variants in cell cycle control pathway confer susceptibility to aggressive prostate carcinoma. <i>Prostate</i> , 2016 , 76, 479-90	4.2	9
268	Key genes involved in the immune response are generally not associated with intraprostatic inflammation in men without a prostate cancer diagnosis: Results from the prostate cancer prevention trial. <i>Prostate</i> , 2016 , 76, 565-74	4.2	5
267	Infectious mononucleosis, other infections and prostate-specific antigen concentration as a marker of prostate involvement during infection. <i>International Journal of Cancer</i> , 2016 , 138, 2221-30	7.5	9
266	Peripheral Zone Inflammation Is Not Strongly Associated With Lower Urinary Tract Symptom Incidence and Progression in the Placebo Arm of the Prostate Cancer Prevention Trial . <i>Prostate</i> , 2016 , 76, 1399-408	4.2	6
265	Integrated clinical, whole-genome, and transcriptome analysis of multisampled lethal metastatic prostate cancer. <i>Journal of Physical Education and Sports Management</i> , 2016 , 2, a000752	2.8	18
264	Inflammation, Microbiota, and Prostate Cancer. <i>European Urology Focus</i> , 2016 , 2, 374-382	5.1	28
263	REVEL: An Ensemble Method for Predicting the Pathogenicity of Rare Missense Variants. <i>American Journal of Human Genetics</i> , 2016 , 99, 877-885	11	722
262	Associations of prostate cancer risk variants with disease aggressiveness: results of the NCI-SPORE Genetics Working Group analysis of 18,343 cases. <i>Human Genetics</i> , 2015 , 134, 439-50	6.3	34
261	The HOXB13 G84E Mutation Is Associated with an Increased Risk for Prostate Cancer and Other Malignancies. <i>Cancer Epidemiology Biomarkers and Prevention</i> , 2015 , 24, 1366-72	4	41
260	Integration of multiethnic fine-mapping and genomic annotation to prioritize candidate functional SNPs at prostate cancer susceptibility regions. <i>Human Molecular Genetics</i> , 2015 , 24, 5603-18	5.6	35
259	The evolutionary history of lethal metastatic prostate cancer. <i>Nature</i> , 2015 , 520, 353-357	50.4	857
258	Cyclin D1 Loss Distinguishes Prostatic Small-Cell Carcinoma from Most Prostatic Adenocarcinomas. <i>Clinical Cancer Research</i> , 2015 , 21, 5619-29	12.9	43
257	Large-scale association analysis in Asians identifies new susceptibility loci for prostate cancer. <i>Nature Communications</i> , 2015 , 6, 8469	17.4	37
256	Do environmental factors modify the genetic risk of prostate cancer?. <i>Cancer Epidemiology Biomarkers and Prevention</i> , 2015 , 24, 213-20	4	9
255	Understanding the mechanisms of androgen deprivation resistance in prostate cancer at the molecular level. <i>European Urology</i> , 2015 , 67, 470-9	10.2	181
254	Variation in genes involved in the immune response and prostate cancer risk in the placebo arm of the Prostate Cancer Prevention Trial. <i>Prostate</i> , 2015 , 75, 1403-18	4.2	23
253	Polymorphisms influencing prostate-specific antigen concentration may bias genome-wide association studies on prostate cancer. <i>Cancer Epidemiology Biomarkers and Prevention</i> , 2015 , 24, 88-93	4	3
252	Generalizability of established prostate cancer risk variants in men of African ancestry. <i>International Journal of Cancer</i> , 2015 , 136, 1210-7	7.5	51

251	AR splice variant 7 (AR-V7) and response to taxanes in men with metastatic castration-resistant prostate cancer (mCRPC).. <i>Journal of Clinical Oncology</i> , 2015 , 33, 138-138	2.2	10
250	Association analysis of 9,560 prostate cancer cases from the International Consortium of Prostate Cancer Genetics confirms the role of reported prostate cancer associated SNPs for familial disease. <i>Human Genetics</i> , 2014 , 133, 347-56	6.3	23
249	Prevalence of the HOXB13 G84E prostate cancer risk allele in men treated with radical prostatectomy. <i>BJU International</i> , 2014 , 113, 830-5	5.6	20
248	Leveraging population admixture to characterize the heritability of complex traits. <i>Nature Genetics</i> , 2014 , 46, 1356-62	36.3	45
247	Rb loss is characteristic of prostatic small cell neuroendocrine carcinoma. <i>Clinical Cancer Research</i> , 2014 , 20, 890-903	12.9	215
246	Telomere length as a risk factor for hereditary prostate cancer. <i>Prostate</i> , 2014 , 74, 359-64	4.2	22
245	Mobile DNA in cancer. Extensive transduction of nonrepetitive DNA mediated by L1 retrotransposition in cancer genomes. <i>Science</i> , 2014 , 345, 1251343	33.3	250
244	A meta-analysis of 87,040 individuals identifies 23 new susceptibility loci for prostate cancer. <i>Nature Genetics</i> , 2014 , 46, 1103-9	36.3	331
243	AR-V7 and resistance to enzalutamide and abiraterone in prostate cancer. <i>New England Journal of Medicine</i> , 2014 , 371, 1028-38	59.2	1753
242	Genome-wide scan of 29,141 African Americans finds no evidence of directional selection since admixture. <i>American Journal of Human Genetics</i> , 2014 , 95, 437-44	11	46
241	Identification of a novel germline SPOP mutation in a family with hereditary prostate cancer. <i>Prostate</i> , 2014 , 74, 983-90	4.2	13
240	Genome-wide association scan for variants associated with early-onset prostate cancer. <i>PLoS ONE</i> , 2014 , 9, e93436	3.7	19
239	A peripheral circulating TH1 cytokine profile is inversely associated with prostate cancer risk in CLUE II. <i>Cancer Epidemiology Biomarkers and Prevention</i> , 2014 , 23, 2561-7	4	17
238	Androgen receptor splice variant, AR-V7, and resistance to enzalutamide and abiraterone in men with metastatic castration-resistant prostate cancer (mCRPC).. <i>Journal of Clinical Oncology</i> , 2014 , 32, 5001-5001	2.2	8
237	Association of the HOXB13 G84E mutation with increased risk for prostate cancer and other malignancies.. <i>Journal of Clinical Oncology</i> , 2014 , 32, 1558-1558	2.2	
236	Genome-wide association study identifies loci at ATF7IP and KLK2 associated with percentage of circulating free PSA. <i>Neoplasia</i> , 2013 , 15, 95-101	6.4	10
235	Loss of PTEN is associated with aggressive behavior in ERG-positive prostate cancer. <i>Cancer Epidemiology Biomarkers and Prevention</i> , 2013 , 22, 2333-44	4	104
234	DNA methylation alterations exhibit intraindividual stability and interindividual heterogeneity in prostate cancer metastases. <i>Science Translational Medicine</i> , 2013 , 5, 169ra10	17.5	190

233	HOXB13 is a susceptibility gene for prostate cancer: results from the International Consortium for Prostate Cancer Genetics (ICPCG). <i>Human Genetics</i> , 2013 , 132, 5-14	6.3	134
232	Genome-wide association study identifies genetic determinants of urine PCA3 levels in men. <i>Neoplasia</i> , 2013 , 15, 448-53	6.4	5
231	Genetic markers associated with early cancer-specific mortality following prostatectomy. <i>Cancer</i> , 2013 , 119, 2405-12	6.4	68
230	Nucleotide resolution analysis of TMPRSS2 and ERG rearrangements in prostate cancer. <i>Journal of Pathology</i> , 2013 , 230, 174-83	9.4	31
229	A meta-analysis of genome-wide association studies to identify prostate cancer susceptibility loci associated with aggressive and non-aggressive disease. <i>Human Molecular Genetics</i> , 2013 , 22, 408-15	5.6	109
228	The G84E mutation of HOXB13 is associated with increased risk for prostate cancer: results from the REDUCE trial. <i>Carcinogenesis</i> , 2013 , 34, 1260-4	4.6	45
227	Global patterns of prostate cancer incidence, aggressiveness, and mortality in men of african descent. <i>Prostate Cancer</i> , 2013 , 2013, 560857	1.9	136
226	A genome-wide assessment of variability in human serum metabolism. <i>Human Mutation</i> , 2013 , 34, 515-24.7	4.7	38
225	Tracking the clonal origin of lethal prostate cancer. <i>Journal of Clinical Investigation</i> , 2013 , 123, 4918-22	15.9	355
224	Infections and inflammation in prostate cancer. <i>American Journal of Clinical and Experimental Urology</i> , 2013 , 1, 3-11	1.6	39
223	The role of genetic markers in the management of prostate cancer. <i>European Urology</i> , 2012 , 62, 577-87	10.2	86
222	Distinct transcriptional programs mediated by the ligand-dependent full-length androgen receptor and its splice variants in castration-resistant prostate cancer. <i>Cancer Research</i> , 2012 , 72, 3457-62	10.1	417
221	Potential impact of adding genetic markers to clinical parameters in predicting prostate biopsy outcomes in men following an initial negative biopsy: findings from the REDUCE trial. <i>European Urology</i> , 2012 , 62, 953-61	10.2	73
220	Identification of a novel NBN truncating mutation in a family with hereditary prostate cancer. <i>Familial Cancer</i> , 2012 , 11, 595-600	3	14
219	Germline mutations in HOXB13 and prostate-cancer risk. <i>New England Journal of Medicine</i> , 2012 , 366, 141-9	59.2	424
218	Association of prostate cancer risk with SNPs in regions containing androgen receptor binding sites captured by ChIP-On-chip analyses. <i>Prostate</i> , 2012 , 72, 376-85	4.2	13
217	Chromosomes 4 and 8 implicated in a genome wide SNP linkage scan of 762 prostate cancer families collected by the ICPCG. <i>Prostate</i> , 2012 , 72, 410-26	4.2	14
216	DIAPH3 governs the cellular transition to the amoeboid tumour phenotype. <i>EMBO Molecular Medicine</i> , 2012 , 4, 743-60	12	69

215	Genome-wide two-locus epistasis scans in prostate cancer using two European populations. <i>Human Genetics</i> , 2012 , 131, 1225-34	6.3	12
214	Validation of prostate cancer risk-related loci identified from genome-wide association studies using family-based association analysis: evidence from the International Consortium for Prostate Cancer Genetics (ICPCG). <i>Human Genetics</i> , 2012 , 131, 1095-103	6.3	18
213	Variation in IL10 and other genes involved in the immune response and in oxidation and prostate cancer recurrence. <i>Cancer Epidemiology Biomarkers and Prevention</i> , 2012 , 21, 1774-82	4	40
212	A genome-wide search for loci interacting with known prostate cancer risk-associated genetic variants. <i>Carcinogenesis</i> , 2012 , 33, 598-603	4.6	27
211	Genome-wide association study identifies a new locus JMJD1C at 10q21 that may influence serum androgen levels in men. <i>Human Molecular Genetics</i> , 2012 , 21, 5222-8	5.6	60
210	Identification of new differentially methylated genes that have potential functional consequences in prostate cancer. <i>PLoS ONE</i> , 2012 , 7, e48455	3.7	42
209	Inherited susceptibility for aggressive prostate cancer. <i>Asian Journal of Andrology</i> , 2012 , 14, 415-8	2.8	6
208	Evaluation of PPP2R2A as a prostate cancer susceptibility gene: a comprehensive germline and somatic study. <i>Cancer Genetics</i> , 2011 , 204, 375-81	2.3	44
207	GENETIC BASIS FOR PROSTATE CANCER 2011 , 39-52		
206	Genome-wide association study of prostate cancer in men of African ancestry identifies a susceptibility locus at 17q21. <i>Nature Genetics</i> , 2011 , 43, 570-3	36.3	171
205	Polygenic risk score improves prostate cancer risk prediction: results from the Stockholm-1 cohort study. <i>European Urology</i> , 2011 , 60, 21-8	10.2	97
204	Inherited genetic markers discovered to date are able to identify a significant number of men at considerably elevated risk for prostate cancer. <i>Prostate</i> , 2011 , 71, 421-30	4.2	34
203	Functional annotation of risk loci identified through genome-wide association studies for prostate cancer. <i>Prostate</i> , 2011 , 71, 955-63	4.2	22
202	A snapshot of the expression signature of androgen receptor splicing variants and their distinctive transcriptional activities. <i>Prostate</i> , 2011 , 71, 1656-67	4.2	159
201	Immunomodulatory IL-18 binding protein is produced by prostate cancer cells and its levels in urine and serum correlate with tumor status. <i>International Journal of Cancer</i> , 2011 , 129, 424-32	7.5	33
200	Genome-wide copy-number variation analysis identifies common genetic variants at 20p13 associated with aggressiveness of prostate cancer. <i>Carcinogenesis</i> , 2011 , 32, 1057-62	4.6	29
199	Human polymorphisms at long non-coding RNAs (lncRNAs) and association with prostate cancer risk. <i>Carcinogenesis</i> , 2011 , 32, 1655-9	4.6	107
198	High-throughput screen identifies novel inhibitors of cancer biomarker ̢-methylacyl coenzyme A racemase (AMACR/P504S). <i>Molecular Cancer Therapeutics</i> , 2011 , 10, 825-38	6.1	38

197	Genome-wide association study identifies new prostate cancer susceptibility loci. <i>Human Molecular Genetics</i> , 2011 , 20, 3867-75	5.6	143
196	Fine mapping of a region of chromosome 11q13 reveals multiple independent loci associated with risk of prostate cancer. <i>Human Molecular Genetics</i> , 2011 , 20, 2869-78	5.6	39
195	Prostate cancer predisposition loci and risk of metastatic disease and prostate cancer recurrence. <i>Clinical Cancer Research</i> , 2011 , 17, 1075-81	12.9	37
194	Large-scale fine mapping of the HNF1B locus and prostate cancer risk. <i>Human Molecular Genetics</i> , 2011 , 20, 3322-9	5.6	22
193	The landscape of recombination in African Americans. <i>Nature</i> , 2011 , 476, 170-5	50.4	243
192	Increased gene copy number of ERG on chromosome 21 but not TMPRSS2-ERG fusion predicts outcome in prostatic adenocarcinomas. <i>Modern Pathology</i> , 2011 , 24, 1511-20	9.8	50
191	A genome-wide survey over the CHIP-on-chip identified androgen receptor-binding genomic regions identifies a novel prostate cancer susceptibility locus at 12q13.13. <i>Cancer Epidemiology Biomarkers and Prevention</i> , 2011 , 20, 2396-403	4	8
190	Validation of genome-wide prostate cancer associations in men of African descent. <i>Cancer Epidemiology Biomarkers and Prevention</i> , 2011 , 20, 23-32	4	79
189	Germ-line sequence variants of PTEN do not have an important role in hereditary and non-hereditary prostate cancer susceptibility. <i>Journal of Human Genetics</i> , 2011 , 56, 496-502	4.3	9
188	PTEN protein loss by immunostaining: analytic validation and prognostic indicator for a high risk surgical cohort of prostate cancer patients. <i>Clinical Cancer Research</i> , 2011 , 17, 6563-73	12.9	266
187	Genetic variants in the LEPR, CRY1, RNASEL, IL4, and ARVCF genes are prognostic markers of prostate cancer-specific mortality. <i>Cancer Epidemiology Biomarkers and Prevention</i> , 2011 , 20, 1928-36	4	58
186	Characterizing genetic risk at known prostate cancer susceptibility loci in African Americans. <i>PLoS Genetics</i> , 2011 , 7, e1001387	6	98
185	A snapshot of the expression signature of androgen receptor splicing variants and their distinctive transcriptional activities 2011 , 71, 1656		1
184	Androgen-induced TOP2B-mediated double-strand breaks and prostate cancer gene rearrangements. <i>Nature Genetics</i> , 2010 , 42, 668-75	36.3	436
183	XMRV: a new virus in prostate cancer?. <i>Cancer Research</i> , 2010 , 70, 10028-33	10.1	68
182	Refining the prostate cancer genetic association within the JAZF1 gene on chromosome 7p15.2. <i>Cancer Epidemiology Biomarkers and Prevention</i> , 2010 , 19, 1349-55	4	21
181	Comparison of two methods for estimating absolute risk of prostate cancer based on single nucleotide polymorphisms and family history. <i>Cancer Epidemiology Biomarkers and Prevention</i> , 2010 , 19, 1083-8	4	13
180	Inherited genetic variant predisposes to aggressive but not indolent prostate cancer. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 2010 , 107, 2136-40	11.5	90

179	Association of 17 prostate cancer susceptibility loci with prostate cancer risk in Chinese men. <i>Prostate</i> , 2010 , 70, 425-32	4.2	47
178	Monocyte chemotactic protein-1 (MCP-1/CCL2) is associated with prostatic growth dysregulation and benign prostatic hyperplasia. <i>Prostate</i> , 2010 , 70, 473-81	4.2	55
177	Association of CASP8 D302H polymorphism with reduced risk of aggressive prostate carcinoma. <i>Prostate</i> , 2010 , 70, 646-53	4.2	15
176	Genome-wide linkage analysis of 1,233 prostate cancer pedigrees from the International Consortium for Prostate Cancer Genetics using novel sumLINK and sumLOD analyses. <i>Prostate</i> , 2010 , 70, 735-44	4.2	22
175	Prostate cancer risk-associated variants reported from genome-wide association studies: meta-analysis and their contribution to genetic Variation. <i>Prostate</i> , 2010 , 70, 1729-38	4.2	55
174	Evaluation of association of HNF1B variants with diverse cancers: collaborative analysis of data from 19 genome-wide association studies. <i>PLoS ONE</i> , 2010 , 5, e10858	3.7	24
173	Acute inflammatory proteins constitute the organic matrix of prostatic corpora amylacea and calculi in men with prostate cancer. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 2009 , 106, 3443-8	11.5	107
172	Macrophage inhibitory cytokine 1: a new prognostic marker in prostate cancer. <i>Clinical Cancer Research</i> , 2009 , 15, 6658-64	12.9	117
171	Prostate cancer risk associated loci in African Americans. <i>Cancer Epidemiology Biomarkers and Prevention</i> , 2009 , 18, 2145-9	4	53
170	Fine mapping association study and functional analysis implicate a SNP in MSMB at 10q11 as a causal variant for prostate cancer risk. <i>Human Molecular Genetics</i> , 2009 , 18, 1368-75	5.6	91
169	Sequence variants at 22q13 are associated with prostate cancer risk. <i>Cancer Research</i> , 2009 , 69, 10-5	10.1	100
168	Ligand-independent androgen receptor variants derived from splicing of cryptic exons signify hormone-refractory prostate cancer. <i>Cancer Research</i> , 2009 , 69, 16-22	10.1	779
167	Association of a germ-line copy number variation at 2p24.3 and risk for aggressive prostate cancer. <i>Cancer Research</i> , 2009 , 69, 2176-9	10.1	68
166	A novel prostate cancer susceptibility locus at 19q13. <i>Cancer Research</i> , 2009 , 69, 2720-3	10.1	48
165	Genetic variants and family history predict prostate cancer similar to prostate-specific antigen. <i>Clinical Cancer Research</i> , 2009 , 15, 1105-11	12.9	33
164	Genetic and epigenetic inactivation of LPL gene in human prostate cancer. <i>International Journal of Cancer</i> , 2009 , 124, 734-8	7.5	28
163	Endoglin (CD105) as a urinary and serum marker of prostate cancer. <i>International Journal of Cancer</i> , 2009 , 124, 664-9	7.5	46
162	Genome-wide expression analysis of recently processed formalin-fixed paraffin embedded human prostate tissues. <i>Prostate</i> , 2009 , 69, 214-8	4.2	15

161	Genetic and epigenetic inactivation of TNFRSF10C in human prostate cancer. <i>Prostate</i> , 2009 , 69, 327-35	4.2	23
160	Comprehensive mutational analysis and mRNA isoform quantification of TP63 in normal and neoplastic human prostate cells. <i>Prostate</i> , 2009 , 69, 559-69	4.2	14
159	Association of reported prostate cancer risk alleles with PSA levels among men without a diagnosis of prostate cancer. <i>Prostate</i> , 2009 , 69, 419-27	4.2	32
158	Association of IL10 and other immune response- and obesity-related genes with prostate cancer in CLUE II. <i>Prostate</i> , 2009 , 69, 874-85	4.2	108
157	Individual and cumulative effect of prostate cancer risk-associated variants on clinicopathologic variables in 5,895 prostate cancer patients. <i>Prostate</i> , 2009 , 69, 1195-205	4.2	86
156	Estimation of absolute risk for prostate cancer using genetic markers and family history. <i>Prostate</i> , 2009 , 69, 1565-72	4.2	69
155	Human prostate-infiltrating CD8+ T lymphocytes are oligoclonal and PD-1+. <i>Prostate</i> , 2009 , 69, 1694-703	4.2	173
154	TMPRSS2-ERG gene fusion status in minute (minimal) prostatic adenocarcinoma. <i>Modern Pathology</i> , 2009 , 22, 1415-22	9.8	38
153	Identification of a new prostate cancer susceptibility locus on chromosome 8q24. <i>Nature Genetics</i> , 2009 , 41, 1055-7	36.3	201
152	Copy number analysis indicates monoclonal origin of lethal metastatic prostate cancer. <i>Nature Medicine</i> , 2009 , 15, 559-65	50.5	513
151	Does diabetes mellitus modify the association between 17q12 risk variant and prostate cancer aggressiveness?. <i>BJU International</i> , 2009 , 104, 1200-3	5.6	5
150	Nuclear MYC protein overexpression is an early alteration in human prostate carcinogenesis. <i>Modern Pathology</i> , 2008 , 21, 1156-67	9.8	301
149	Evidence for two independent prostate cancer risk-associated loci in the HNF1B gene at 17q12. <i>Nature Genetics</i> , 2008 , 40, 1153-5	36.3	139
148	Common sequence variants on 2p15 and Xp11.22 confer susceptibility to prostate cancer. <i>Nature Genetics</i> , 2008 , 40, 281-3	36.3	327
147	A multigenic approach to evaluating prostate cancer risk in a systematic replication study. <i>Cancer Genetics and Cytogenetics</i> , 2008 , 183, 94-8		6
146	Cumulative association of five genetic variants with prostate cancer. <i>New England Journal of Medicine</i> , 2008 , 358, 910-9	59.2	526
145	Homozygous deletions and recurrent amplifications implicate new genes involved in prostate cancer. <i>Neoplasia</i> , 2008 , 10, 897-907	6.4	86
144	Phenotypic analysis of prostate-infiltrating lymphocytes reveals TH17 and Treg skewing. <i>Clinical Cancer Research</i> , 2008 , 14, 3254-61	12.9	314

143	Identification and characterization of novel SNPs in CHEK2 in Ashkenazi Jewish men with prostate cancer. <i>Cancer Letters</i> , 2008 , 270, 173-80	9.9	15
142	DNA hypomethylation arises later in prostate cancer progression than CpG island hypermethylation and contributes to metastatic tumor heterogeneity. <i>Cancer Research</i> , 2008 , 68, 8954-67	10.1	209
141	Association of prostate cancer risk variants with clinicopathologic characteristics of the disease. <i>Clinical Cancer Research</i> , 2008 , 14, 5819-24	12.9	55
140	alpha-Catenin overrides Src-dependent activation of beta-catenin oncogenic signaling. <i>Molecular Cancer Therapeutics</i> , 2008 , 7, 1386-97	6.1	21
139	A molecular analysis of prokaryotic and viral DNA sequences in prostate tissue from patients with prostate cancer indicates the presence of multiple and diverse microorganisms. <i>Prostate</i> , 2008 , 68, 306-20	4.2	131
138	Carbohydrate restriction, prostate cancer growth, and the insulin-like growth factor axis. <i>Prostate</i> , 2008 , 68, 11-9	4.2	116
137	Chromosome 8q24 risk variants in hereditary and non-hereditary prostate cancer patients. <i>Prostate</i> , 2008 , 68, 489-97	4.2	35
136	Association between sequence variants at 17q12 and 17q24.3 and prostate cancer risk in European and African Americans. <i>Prostate</i> , 2008 , 68, 691-7	4.2	39
135	Cytokine profiling of prostatic fluid from cancerous prostate glands identifies cytokines associated with extent of tumor and inflammation. <i>Prostate</i> , 2008 , 68, 872-82	4.2	45
134	Cumulative effect of five genetic variants on prostate cancer risk in multiple study populations. <i>Prostate</i> , 2008 , 68, 1257-62	4.2	44
133	GOLPH2 and MYO6: putative prostate cancer markers localized to the Golgi apparatus. <i>Prostate</i> , 2008 , 68, 1387-95	4.2	61
132	An evaluation of PCR primer sets used for detection of <i>Propionibacterium acnes</i> in prostate tissue samples. <i>Prostate</i> , 2008 , 68, 1492-5	4.2	30
131	Design, synthesis, and in vitro testing of alpha-methylacyl-CoA racemase inhibitors. <i>Journal of Medicinal Chemistry</i> , 2007 , 50, 2700-7	8.3	43
130	Assembly of inflammation-related genes for pathway-focused genetic analysis. <i>PLoS ONE</i> , 2007 , 2, e1035.7	5.7	73
129	Acne and risk of prostate cancer. <i>International Journal of Cancer</i> , 2007 , 121, 2688-92	7.5	66
128	Multiple genomic alterations on 21q22 predict various TMPRSS2/ERG fusion transcripts in human prostate cancers. <i>Genes Chromosomes and Cancer</i> , 2007 , 46, 972-80	5	40
127	Germline copy number polymorphisms involving larger than 100 kb are uncommon in normal subjects. <i>Prostate</i> , 2007 , 67, 227-33	4.2	2
126	RNAseL Arg462Gln polymorphism and prostate cancer in PLCO. <i>Prostate</i> , 2007 , 67, 849-54	4.2	21

125	DNA copy number alterations in prostate cancers: a combined analysis of published CGH studies. <i>Prostate</i> , 2007 , 67, 692-700	4.2	129
124	Mutational analysis of SPANX genes in families with X-linked prostate cancer. <i>Prostate</i> , 2007 , 67, 820-8	4.2	18
123	Polymorphic variants in alpha-methylacyl-CoA racemase and prostate cancer. <i>Prostate</i> , 2007 , 67, 1487-97	4.2	20
122	Genome-wide association study identifies a second prostate cancer susceptibility variant at 8q24. <i>Nature Genetics</i> , 2007 , 39, 631-7	36.3	739
121	Inflammation in prostate carcinogenesis. <i>Nature Reviews Cancer</i> , 2007 , 7, 256-69	31.3	1168
120	Fine-mapping the putative chromosome 17q21-22 prostate cancer susceptibility gene to a 10 cM region based on linkage analysis. <i>Human Genetics</i> , 2007 , 121, 49-55	6.3	28
119	Two genome-wide association studies of aggressive prostate cancer implicate putative prostate tumor suppressor gene DAB2IP. <i>Journal of the National Cancer Institute</i> , 2007 , 99, 1836-44	9.7	218
118	Association between two unlinked loci at 8q24 and prostate cancer risk among European Americans. <i>Journal of the National Cancer Institute</i> , 2007 , 99, 1525-33	9.7	120
117	Deletion of a small consensus region at 6q15, including the MAP3K7 gene, is significantly associated with high-grade prostate cancers. <i>Clinical Cancer Research</i> , 2007 , 13, 5028-33	12.9	57
116	Integration of somatic deletion analysis of prostate cancers and germline linkage analysis of prostate cancer families reveals two small consensus regions for prostate cancer genes at 8p. <i>Cancer Research</i> , 2007 , 67, 4098-103	10.1	30
115	Compelling evidence for a prostate cancer gene at 22q12.3 by the International Consortium for Prostate Cancer Genetics. <i>Human Molecular Genetics</i> , 2007 , 16, 1271-8	5.6	30
114	Genetic variability in inflammation pathways and prostate cancer risk. <i>Urologic Oncology: Seminars and Original Investigations</i> , 2007 , 25, 250-9	2.8	42
113	Comprehensive assessment of DNA copy number alterations in human prostate cancers using Affymetrix 100K SNP mapping array. <i>Genes Chromosomes and Cancer</i> , 2006 , 45, 1018-32	5	58
112	Germ-line mutation of NKX3.1 cosegregates with hereditary prostate cancer and alters the homeodomain structure and function. <i>Cancer Research</i> , 2006 , 66, 69-77	10.1	40
111	Truncating variants in p53AIP1 disrupting DNA damage-induced apoptosis are associated with prostate cancer risk. <i>Cancer Research</i> , 2006 , 66, 10302-7	10.1	9
110	A novel role of myosin VI in human prostate cancer. <i>American Journal of Pathology</i> , 2006 , 169, 1843-54	5.8	112
109	Phenotypic characterization of telomerase-immortalized primary non-malignant and malignant tumor-derived human prostate epithelial cell lines. <i>Experimental Cell Research</i> , 2006 , 312, 831-43	4.2	66
108	Sexually transmitted infections and prostatic inflammation/cell damage as measured by serum prostate specific antigen concentration. <i>Journal of Urology</i> , 2006 , 175, 1937-42	2.5	51

107	Meta-analysis of association of rare mutations and common sequence variants in the MSR1 gene and prostate cancer risk. <i>Prostate</i> , 2006 , 66, 728-37	4.2	32
106	Germline ATBF1 mutations and prostate cancer risk. <i>Prostate</i> , 2006 , 66, 1082-5	4.2	19
105	Systematic replication study of reported genetic associations in prostate cancer: Strong support for genetic variation in the androgen pathway. <i>Prostate</i> , 2006 , 66, 1729-43	4.2	60
104	A comprehensive association study for genes in inflammation pathway provides support for their roles in prostate cancer risk in the CAPS study. <i>Prostate</i> , 2006 , 66, 1556-64	4.2	43
103	Two-locus genome-wide linkage scan for prostate cancer susceptibility genes with an interaction effect. <i>Human Genetics</i> , 2006 , 118, 716-24	6.3	15
102	A combined genomewide linkage scan of 1,233 families for prostate cancer-susceptibility genes conducted by the international consortium for prostate cancer genetics. <i>American Journal of Human Genetics</i> , 2005 , 77, 219-29	11	129
101	Evidence for a general cancer susceptibility locus at 3p24 in families with hereditary prostate cancer. <i>Cancer Letters</i> , 2005 , 219, 177-82	9.9	1
100	Comprehensive genetic evaluation of common E-cadherin sequence variants and prostate cancer risk: strong confirmation of functional promoter SNP. <i>Human Genetics</i> , 2005 , 118, 339-47	6.3	27
99	A major locus for hereditary prostate cancer in Finland: localization by linkage disequilibrium of a haplotype in the HPCX region. <i>Human Genetics</i> , 2005 , 117, 307-16	6.3	27
98	Explaining racial differences in prostate cancer in the United States: sociology or biology?. <i>Prostate</i> , 2005 , 62, 243-52	4.2	102
97	Peroxisomal branched chain fatty acid beta-oxidation pathway is upregulated in prostate cancer. <i>Prostate</i> , 2005 , 63, 316-23	4.2	129
96	Sequence variation within the 5Regulatory regions of the vitamin D binding protein and receptor genes and prostate cancer risk. <i>Prostate</i> , 2005 , 64, 272-82	4.2	31
95	Modulation of CXCL14 (BRAK) expression in prostate cancer. <i>Prostate</i> , 2005 , 64, 67-74	4.2	85
94	Genome-wide screen for prostate cancer susceptibility genes in men with clinically significant disease. <i>Prostate</i> , 2005 , 64, 356-61	4.2	42
93	Dynamic structure of the SPANX gene cluster mapped to the prostate cancer susceptibility locus HPCX at Xq27. <i>Genome Research</i> , 2005 , 15, 1477-86	9.7	37
92	A nonclassic CCAAT enhancer element binding protein binding site contributes to alpha-methylacyl-CoA racemase expression in prostate cancer. <i>Molecular Cancer Research</i> , 2005 , 3, 110-8	6.6	13
91	Stronger association between obesity and biochemical progression after radical prostatectomy among men treated in the last 10 years. <i>Clinical Cancer Research</i> , 2005 , 11, 2883-8	12.9	54
90	Prostate carcinogenesis and inflammation: emerging insights. <i>Carcinogenesis</i> , 2005 , 26, 1170-81	4.6	295

89	A germline DNA polymorphism enhances alternative splicing of the KLF6 tumor suppressor gene and is associated with increased prostate cancer risk. <i>Cancer Research</i> , 2005 , 65, 1213-22	10.1	182
88	Sequence variants in Toll-like receptor gene cluster (TLR6-TLR1-TLR10) and prostate cancer risk. <i>Journal of the National Cancer Institute</i> , 2005 , 97, 525-32	9.7	139
87	COX-2 gene promoter haplotypes and prostate cancer risk. <i>Carcinogenesis</i> , 2004 , 25, 961-6	4.6	85
86	Sequence variants of toll-like receptor 4 are associated with prostate cancer risk: results from the CAncer Prostate in Sweden Study. <i>Cancer Research</i> , 2004 , 64, 2918-22	10.1	199
85	Combined genome-wide scan for prostate cancer susceptibility genes. <i>Journal of the National Cancer Institute</i> , 2004 , 96, 1240-7	9.7	65
84	Identification of a prostate cancer susceptibility locus on chromosome 7q11-21 in Jewish families. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 2004 , 101, 1939-44	11.5	20
83	A polymorphism in the CDKN1B gene is associated with increased risk of hereditary prostate cancer. <i>Cancer Research</i> , 2004 , 64, 1997-9	10.1	70
82	Identification of aryl hydrocarbon receptor as a putative Wnt/beta-catenin pathway target gene in prostate cancer cells. <i>Cancer Research</i> , 2004 , 64, 2523-33	10.1	56
81	H6D polymorphism in macrophage-inhibitory cytokine-1 gene associated with prostate cancer. <i>Journal of the National Cancer Institute</i> , 2004 , 96, 1248-54	9.7	99
80	Improved biomarkers for prostate cancer: a definite need. <i>Journal of the National Cancer Institute</i> , 2004 , 96, 813-5	9.7	21
79	Sequence variants in the 3R->5Rdeoxyribonuclease TREX2: identification in a genetic screen and effects on catalysis by the recombinant proteins. <i>Advances in Enzyme Regulation</i> , 2004 , 44, 37-49		10
78	Mutational analysis of PINX1 in hereditary prostate cancer. <i>Prostate</i> , 2004 , 60, 298-302	4.2	22
77	Trefoil factor 3 overexpression in prostatic carcinoma: prognostic importance using tissue microarrays. <i>Prostate</i> , 2004 , 61, 215-27	4.2	73
76	Expression mapping at 12p12-13 in advanced prostate carcinoma. <i>International Journal of Cancer</i> , 2004 , 109, 668-72	7.5	20
75	Pathological and molecular mechanisms of prostate carcinogenesis: implications for diagnosis, detection, prevention, and treatment. <i>Journal of Cellular Biochemistry</i> , 2004 , 91, 459-77	4.7	143
74	Hypermethylation of CpG islands in primary and metastatic human prostate cancer. <i>Cancer Research</i> , 2004 , 64, 1975-86	10.1	416
73	Interaction effect of PTEN and CDKN1B chromosomal regions on prostate cancer linkage. <i>Human Genetics</i> , 2004 , 115, 255-62	6.3	14
72	Cyclooxygenases in cancer: progress and perspective. <i>Cancer Letters</i> , 2004 , 215, 1-20	9.9	341

71	Alpha-methylacyl-CoA racemase: a variably sensitive immunohistochemical marker for the diagnosis of small prostate cancer foci on needle biopsy. <i>American Journal of Surgical Pathology</i> , 2003 , 27, 1128-33	6.7	97
70	Xq27-28 deletions in prostate carcinoma. <i>Genes Chromosomes and Cancer</i> , 2003 , 37, 381-8	5	11
69	Polymorphisms in the CYP1A1 gene are associated with prostate cancer risk. <i>International Journal of Cancer</i> , 2003 , 106, 375-8	7.5	49
68	Evaluation of SRD5A2 sequence variants in susceptibility to hereditary and sporadic prostate cancer. <i>Prostate</i> , 2003 , 56, 37-44	4.2	19
67	Decreased gene expression of steroid 5 alpha-reductase 2 in human prostate cancer: implications for finasteride therapy of prostate carcinoma. <i>Prostate</i> , 2003 , 57, 134-9	4.2	98
66	Genome-wide scan for prostate cancer susceptibility genes in the Johns Hopkins hereditary prostate cancer families. <i>Prostate</i> , 2003 , 57, 320-5	4.2	74
65	Human prostate cancer precursors and pathobiology. <i>Urology</i> , 2003 , 62, 55-62	1.6	212
64	Familial aggregation of bothersome benign prostatic hyperplasia symptoms. <i>Urology</i> , 2003 , 61, 781-5	1.6	21
63	Pathological and molecular aspects of prostate cancer. <i>Lancet, The</i> , 2003 , 361, 955-64	40	361
62	Prostate cancer. <i>New England Journal of Medicine</i> , 2003 , 349, 366-81	59.2	883
61	Common sequence variants of the macrophage scavenger receptor 1 gene are associated with prostate cancer risk. <i>American Journal of Human Genetics</i> , 2003 , 72, 208-12	11	81
60	Looking beyond morphology: cancer gene expression profiling using DNA microarrays. <i>Cancer Investigation</i> , 2003 , 21, 937-49	2.1	38
59	Effects of RNase L mutations associated with prostate cancer on apoptosis induced by 2R5Roligoadenylates. <i>Cancer Research</i> , 2003 , 63, 6795-801	10.1	118
58	Alpha-methylacyl-CoA racemase as an androgen-independent growth modifier in prostate cancer. <i>Cancer Research</i> , 2003 , 63, 7365-76	10.1	93
57	Germline sequence variants of the LZTS1 gene are associated with prostate cancer risk. <i>Cancer Genetics and Cytogenetics</i> , 2002 , 137, 1-7		19
56	Focus on prostate cancer. <i>Cancer Cell</i> , 2002 , 2, 113-6	24.3	74
55	Transmission/disequilibrium tests of androgen receptor and glutathione S-transferase pi variants in prostate cancer families. <i>International Journal of Cancer</i> , 2002 , 98, 938-42	7.5	8
54	Polymorphic GGC repeats in the androgen receptor gene are associated with hereditary and sporadic prostate cancer risk. <i>Human Genetics</i> , 2002 , 110, 122-9	6.3	64

53	CYP3A4-V and prostate cancer in African Americans: causal or confounding association because of population stratification?. <i>Human Genetics</i> , 2002 , 110, 553-60	6.3	136
52	Gene expression signature of benign prostatic hyperplasia revealed by cDNA microarray analysis. <i>Prostate</i> , 2002 , 51, 189-200	4.2	110
51	Mutational analysis of ETV6 in prostate carcinoma. <i>Prostate</i> , 2002 , 52, 305-10	4.2	16
50	Sequence variants in the human 25-hydroxyvitamin D3 1-alpha-hydroxylase (CYP27B1) gene are not associated with prostate cancer risk. <i>Prostate</i> , 2002 , 53, 175-8	4.2	19
49	In vitro evidence for complex modes of nuclear beta-catenin signaling during prostate growth and tumorigenesis. <i>Oncogene</i> , 2002 , 21, 2679-94	9.2	145
48	Ligand-dependent inhibition of beta-catenin/TCF signaling by androgen receptor. <i>Oncogene</i> , 2002 , 21, 8453-69	9.2	133
47	Germline mutations and sequence variants of the macrophage scavenger receptor 1 gene are associated with prostate cancer risk. <i>Nature Genetics</i> , 2002 , 32, 321-5	36.3	283
46	Physical and transcript map of the hereditary prostate cancer region at xq27. <i>Genomics</i> , 2002 , 79, 41-50	4.3	23
45	High mobility group protein I(Y): a candidate architectural protein for chromosomal rearrangements in prostate cancer cells. <i>Cancer Research</i> , 2002 , 62, 647-51	10.1	38
44	Joint effect of HSD3B1 and HSD3B2 genes is associated with hereditary and sporadic prostate cancer susceptibility. <i>Cancer Research</i> , 2002 , 62, 1784-9	10.1	52
43	Alpha-methylacyl-CoA racemase: a new molecular marker for prostate cancer. <i>Cancer Research</i> , 2002 , 62, 2220-6	10.1	339
42	Associations between hOGG1 sequence variants and prostate cancer susceptibility. <i>Cancer Research</i> , 2002 , 62, 2253-7	10.1	105
41	Sequence variants of alpha-methylacyl-CoA racemase are associated with prostate cancer risk. <i>Cancer Research</i> , 2002 , 62, 6485-8	10.1	39
40	Linkage of prostate cancer susceptibility loci to chromosome 1. <i>Human Genetics</i> , 2001 , 108, 335-45	6.3	79
39	Methylation and mutational analysis of p27(kip1) in prostate carcinoma. <i>Prostate</i> , 2001 , 48, 248-53	4.2	33
38	Linkage and association of CYP17 gene in hereditary and sporadic prostate cancer. <i>International Journal of Cancer</i> , 2001 , 95, 354-9	7.5	42
37	Multiple antibodies to titin immunoreact with AHNAK and localize to the mitotic spindle machinery. <i>Cytoskeleton</i> , 2001 , 50, 101-13		16
36	Evidence for a prostate cancer linkage to chromosome 20 in 159 hereditary prostate cancer families. <i>Human Genetics</i> , 2001 , 108, 430-5	6.3	46

35	GSTP1 CpG island hypermethylation is responsible for the absence of GSTP1 expression in human prostate cancer cells. <i>American Journal of Pathology</i> , 2001 , 159, 1815-26	5.8	180
34	Evaluation of linkage and association of HPC2/ELAC2 in patients with familial or sporadic prostate cancer. <i>American Journal of Human Genetics</i> , 2001 , 68, 901-11	11	87
33	Linkage and association studies of prostate cancer susceptibility: evidence for linkage at 8p22-23. <i>American Journal of Human Genetics</i> , 2001 , 69, 341-50	11	127
32	Detection and analysis of beta-catenin mutations in prostate cancer. <i>Prostate</i> , 2000 , 45, 323-34	4.2	156
31	G(1)/S cell cycle proteins as markers of aggressive prostate carcinoma. <i>Urology</i> , 2000 , 55, 316-22	1.6	13
30	LOSS OF HETEROZYGOSITY AT 12P12 $\bar{3}$ IN PRIMARY AND METASTATIC PROSTATE ADENOCARCINOMA. <i>Journal of Urology</i> , 2000 , 164, 192-196	2.5	49
29	Deletion mapping at 12p12 $\bar{3}$ in metastatic prostate cancer 1999 , 25, 270-276		34
28	No evidence for a role of BRCA1 or BRCA2 mutations in Ashkenazi Jewish families with hereditary prostate cancer. <i>Prostate</i> , 1999 , 39, 280-4	4.2	42
27	In Swedish families with hereditary prostate cancer, linkage to the HPC1 locus on chromosome 1q24-25 is restricted to families with early-onset prostate cancer. <i>American Journal of Human Genetics</i> , 1999 , 65, 134-40	11	70
26	Evidence for a prostate cancer susceptibility locus on the X chromosome. <i>Nature Genetics</i> , 1998 , 20, 175- 163 3	3.3	592
25	E1A transformed normal human prostate epithelial cells contain a 16q deletion. <i>Cancer Genetics and Cytogenetics</i> , 1998 , 103, 155-63		5
24	BIOLOGICAL AGGRESSIVENESS OF HEREDITARY PROSTATE CANCER: LONG-TERM EVALUATION FOLLOWING RADICAL PROSTATECTOMY. <i>Journal of Urology</i> , 1998 , 160, 660-663	2.5	59
23	VITAMIN D RECEPTOR POLYMORPHISMS AND LETHAL PROSTATE CANCER. <i>Journal of Urology</i> , 1998 , 160, 1405-1409	2.5	49
22	Molecular advances in prostate cancer. <i>Current Opinion in Oncology</i> , 1997 , 9, 101-7	4.2	56
21	Genomic organization of the human KAI1 metastasis-suppressor gene. <i>Genomics</i> , 1997 , 41, 25-32	4.3	57
20	Deletional, mutational, and methylation analyses of CDKN2 (p16/MTS1) in primary and metastatic prostate cancer. <i>Genes Chromosomes and Cancer</i> , 1997 , 19, 90-96	5	146
19	Relation between aberrant alpha-catenin expression and loss of E-cadherin function in prostate cancer. <i>International Journal of Cancer</i> , 1997 , 74, 374-7	7.5	71
18	Physical mapping of chromosome 8p22 markers and their homozygous deletion in a metastatic prostate cancer. <i>Genomics</i> , 1996 , 35, 46-54	4.3	101

17	Structure and methylation-associated silencing of a gene within a homozygously deleted region of human chromosome band 8p22. <i>Genomics</i> , 1996 , 35, 55-65	4.3	108
16	DNA methylation, molecular genetic, and linkage studies in prostate cancer. <i>Prostate</i> , 1996 , 29, 36-44	4.2	22
15	Allelic loss of the retinoblastoma gene in primary human prostatic adenocarcinomas. <i>Prostate</i> , 1995 , 26, 35-9	4.2	110
14	Frequency of homozygous deletion at p16/CDKN2 in primary human tumours. <i>Nature Genetics</i> , 1995 , 11, 210-2	36.3	554
13	Evaluation of serum and seminal plasma markers in the diagnosis of canine prostatic disorders. <i>Journal of Veterinary Internal Medicine</i> , 1995 , 9, 149-53	3.1	65
12	Molecular genetics and chromosomal alterations in prostate cancer. <i>Cancer</i> , 1995 , 75, 2004-2012	6.4	27
11	Frequent loss of chromosome arms 8p and 13q in collecting duct carcinoma (CDC) of the kidney. <i>Genes Chromosomes and Cancer</i> , 1995 , 12, 76-80	5	64
10	Interleukin-2 transfected prostate cancer cells generate a local antitumor effect in vivo. <i>Prostate</i> , 1994 , 24, 244-51	4.2	45
9	Molecular and cellular changes associated with the acquisition of metastatic ability by prostatic cancer cells. <i>Prostate</i> , 1994 , 25, 249-65	4.2	70
8	Assignment of the human alpha-catenin gene (CTNNA1) to chromosome 5q21-q22. <i>Genomics</i> , 1994 , 19, 188-90	4.3	39
7	Hereditary prostate cancer: epidemiologic and clinical features. <i>Journal of Urology</i> , 1993 , 150, 797-802	2.5	437
6	Molecular and cellular markers for metastatic prostate cancer. <i>Cancer and Metastasis Reviews</i> , 1993 , 12, 3-10	9.6	17
5	Effect of pentosan, a novel cancer chemotherapeutic agent, on prostate cancer cell growth and motility. <i>Prostate</i> , 1992 , 20, 233-41	4.2	21
4	Titin, a huge, elastic sarcomeric protein with a probable role in morphogenesis. <i>BioEssays</i> , 1991 , 13, 157-61	4.1	60
3	The effects of basic fibroblast growth factor and suramin on cell motility and growth of rat prostate cancer cells. <i>Journal of Urology</i> , 1991 , 145, 199-202	2.5	63
2	Differential effects of growth factor antagonists on neoplastic and normal prostatic cells. <i>Prostate</i> , 1990 , 17, 327-36	4.2	15
1	Establishment and characterization of seven Dunning rat prostatic cancer cell lines and their use in developing methods for predicting metastatic abilities of prostatic cancers. <i>Prostate</i> , 1986 , 9, 261-81	4.2	350